Get the Stockscreener App
5.26
2.14%
0.11
Design Therapeutics Inc stock is traded at $5.26, with a volume of 176.51K.
It is up +2.14% in the last 24 hours and up +23.76% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$5.15
Open:
$5.2
24h Volume:
176.51K
Relative Volume:
1.70
Market Cap:
$299.55M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-4.3833
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
-1.31%
1M Performance:
+23.76%
6M Performance:
+7.13%
1Y Performance:
+7.13%
1-Day Range:
$5.11
$5.275
1-Week Range:
$4.68
$5.60
52-Week Range:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
5.26 | 307.52M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Will Design Therapeutics Inc. rebound enough to break evenJuly 2025 Drop Watch & Verified Technical Trade Signals - Newser
Historical volatility pattern of Design Therapeutics Inc. visualized2025 Year in Review & Fast Gain Stock Trading Tips - Newser
Will a bounce in Design Therapeutics Inc. offer an exitWeekly Earnings Recap & Real-Time Stock Price Movement Reports - Newser
How to use a screener to detect Design Therapeutics Inc. breakoutsProduct Launch & Short-Term Trading Opportunity Alerts - Newser
Backtesting results for Design Therapeutics Inc. trading strategiesBuy Signal & Precise Swing Trade Alerts - Newser
Combining machine learning predictions for Design Therapeutics Inc.Earnings Summary Report & Safe Capital Growth Stock Tips - Newser
Visual trend scoring systems applied to Design Therapeutics Inc.Dip Buying & Smart Allocation Stock Reports - Newser
Design Therapeutics Sees Increased R&D Expenses Amid $36.8M Net Loss - AInvest
Design Therapeutics Reports Increased R&D Expenses Amid Net Loss - TipRanks
What technical models suggest about Design Therapeutics Inc.’s comebackJuly 2025 Sector Moves & Consistent Profit Trade Alerts - Newser
Price action breakdown for Design Therapeutics Inc.2025 Price Momentum & Risk Controlled Stock Alerts - Newser
How to build a custom watchlist for Design Therapeutics Inc.2025 Volatility Report & Weekly High Momentum Picks - Newser
Can technical indicators confirm Design Therapeutics Inc.’s reversal2025 Dividend Review & Risk Managed Investment Strategies - Newser
Why Design Therapeutics Inc. is moving today2025 Earnings Impact & Community Driven Trade Alerts - Newser
Can volume confirm reversal in Design Therapeutics Inc.2025 Stock Rankings & Daily Momentum Trading Reports - Newser
Smart tools for monitoring Design Therapeutics Inc.’s price action2025 Key Lessons & High Accuracy Investment Signals - Newser
Using Bollinger Bands to evaluate Design Therapeutics Inc.Quarterly Profit Summary & Smart Allocation Stock Reports - Newser
Watch for Trend Continuation in Design Therapeutics Inc. Next Week2025 Valuation Update & Accurate Intraday Trade Tips - thegnnews.com
Will Design Therapeutics Inc. stock recover after recent dropJuly 2025 Retail & Capital Efficiency Focused Ideas - Newser
Will Design Therapeutics Inc. continue its uptrendAnalyst Upgrade & Risk Controlled Daily Trade Plans - Newser
Design Therapeutics (NASDAQ:DSGN) Trading Up 1.3% – Time to Buy? - Defense World
Myotonic Dystrophy Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma, Lupin - Barchart.com
News impact scoring models applied to Design Therapeutics Inc.July 2025 Review & Technical Analysis for Trade Confirmation - Newser
Is Design Therapeutics Inc. stock ready for a breakoutGap Down & Long-Term Capital Growth Strategies - Newser
What momentum shifts mean for Design Therapeutics Inc.Quarterly Growth Report & Accurate Intraday Trading Signals - Newser
Trend analysis for Design Therapeutics Inc. this weekWeekly Trade Recap & Verified Momentum Watchlists - Newser
How sentiment analysis helps forecast Design Therapeutics Inc.2025 Risk Factors & Expert Curated Trade Setups - Newser
Heatmap analysis for Design Therapeutics Inc. and competitorsJuly 2025 Short Interest & Short-Term High Return Strategies - Newser
Design Therapeutics Maintains Hold Rating Amid Regulatory Hurdles and Financial Caution. - AInvest
Published on: 2025-08-16 20:38:55 - metal.it
Will breakout in Design Therapeutics Inc. lead to full recoveryJuly 2025 Outlook & Long Hold Capital Preservation Plans - Newser
Design Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayJuly 2025 Recap & Technical Pattern Based Buy Signals - Newser
Q3 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World
Long term hold vs stop loss in Design Therapeutics Inc.2025 Technical Patterns & Consistent Profit Trade Alerts - Newser
Can momentum traders help lift Design Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - Newser
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):